Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Hindu
The Hindu
National
Special Correspondent

FORGOTTEN HISTORY: Consortium with bharat biotech to get 19 3 mn for advanced jab - The Untold Story

The Coalition for Epidemic Preparedness Innovations (CEPI) will be providing up to $19.3 million to support development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium consisting of Covaxin maker Bharat Biotech, the University of Sydney, and ExcellGene SA, Switzerland.

The funding will support the consortium as it seeks to establish pre-clinical and clinical proof of concept for an adjuvanted sub unit vaccine designed to provide broad protection against all known SARS-CoV-2 variants of concern, as well as future variants of the virus which have not yet emerged, CEPI said on Tuesday.

The researchers will get the funding to conduct activities, including immunogen design, preclinical studies, manufacturing process development and a Phase 1 clinical trial.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.